Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993842 | 0.93 | BACE1 (0.52) | BACE1BACE2CTSDCTSALMNA | |
| SCHEMBL8284275 | 0.92 | BACE1 (0.50) | BACE1BACE2CTSDCTSA | |
| SCHEMBL8285043 | 0.92 | BACE1 (0.51) | BACE1BACE2CTSDCTSAMYC | |
| SCHEMBL12993840 | 0.92 | BACE1 (0.51) | BACE1BACE2CTSDCTSAMYC | |
| SCHEMBL8285933 | 0.91 | BACE1 (0.49) | BACE1BACE2CTSDCTSAMYC | |
| SCHEMBL12993801 | 0.90 | BACE1 (0.52) | BACE1BACE2CTSDCTSAROCK2 | |
| SCHEMBL8285862 | 0.89 | BACE1 (0.69) | BACE1BACE2ROCK2ROCK1 | |
| SCHEMBL13043562 | 0.89 | BACE1 (0.55) | BACE1BACE2CTSDBRD4 | |
| SCHEMBL3595507 | 0.89 | BACE1 (0.52) | BACE1BACE2CTSAMYCWDR5 | |
| SCHEMBL3598702 | 0.89 | BACE1 (0.52) | BACE1BACE2CTSAMYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847100-B2 | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885CTSD 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.